Novartis Says Gleevec Antitrust Suit Should Remain Paused
End payors accusing Novartis Pharmaceuticals of violating antitrust laws by filing an invalid patent for leukemia drug Gleevec and starting sham litigation over it shouldn't get to try to lift a...To view the full article, register now.
Already a subscriber? Click here to view full article